The Dry Eye Zone

Rebecca's Blog

-

Drug news: SarCode SAR1118

New to me. Very early stages but I've added it to the clinicals roundup.

SARcode Announces Results of Phase 1 Trial of SAR 1118 Ophthalmic Solution in Healthy Adult Subjects
(March 30 press release)

SAN FRANCISCO--(BUSINESS WIRE)--SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers. SAR 1118 was well-tolerated and demonstrated a favorable safety profile when administered by topical ocular instillation up to three times daily at dose strengths of up to 5%....

Based upon these results, SARcode has selected dose strengths and dose schedules for its Phase 2 programs in allergic conjunctivitis and dry eye (keratoconjunctivitis sicca). Data for these programs is expected in 2009. With emerging data in preclinical animal models, SARcode may choose to pursue other ocular inflammatory conditions including diabetic retinopathy and age-related macular degeneration in the near future.

RebeccaComment